Impact of Intravenous Iron Treatment of Preoperative Anemia in Patients With LEAD (IRONPAD) (IRONPAD)

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    240
  • sponsor
    Biocruces Bizkaia Health Research Institute
Updated on 20 June 2022
iron
anemia
iron therapy
ferric carboxymaltose

Summary

Introduction: Anaemia due to iron and vitamin deficiency among patients with critical limb ischemia is high (>50%). The prevalence of a higher rate of anaemia extends into the three months prior to revascularization surgery, it is associated with longer hospital stays and more transfusions in addition to being a factor in poor prognoses. Study and treatment of anaemia within the perioperative period could improve the surgical outcomes, including the recovery and the quality of patients' lives. There are several types of intravenous iron preparations with different administration protocols, but there is not a consensus on the timing and type of the appropriate iron therapy. To the best of our knowledge, there is no data on the performance of intravenous iron in the management of preoperative anaemia in patients with peripheral artery disease (PAD) in vascular surgery.

Methods and analysis: The IRONPAD Study is a phase IV randomised controlled trial with two branches of treatment on the efficacy of intravenous iron therapy for the optimisation of blood use and prognosis in the perioperative period of patients with anaemia undergoing revascularisation for chronic lower limb ischemia. The study randomises 240 patients with anaemia to: treat with a single intravenous dose of ferric carboxymaltose (1000 mg) or no treatment vs oral iron supplements (if severe anaemia) a minimum of two days prior to lower limb revascularisation surgery. The primary outcome is to reduce the incidence of transfusion from randomisation up to 30+7 days after the main surgery. The secondary outcomes will be included to establish the optimal preoperative moment of increased intravenous iron administration, to raise haemoglobin levels; to study the evolution of haemoglobin from inclusion to 30+7 days after surgery; and to determine the impact of anaemia and its treatment on the length of hospital stay, morbidity and mortality, as well as the quality of life in this period.

Description

The IRONPAD Study is a phase IV randomised controlled trial with two branches of treatment on the efficacy of intravenous iron therapy for the optimisation of blood use and prognosis in the perioperative period of patients with anaemia undergoing revascularisation for chronic lower limb ischemia.

Patients admitted to hospital with anaemia and indication of elective revascularisation surgery for chronic ischemia of the lower limbs will be eligible for screening. Anaemia in this study is established following the WHO criteria with haemoglobin (Hb) <130 g/L in men and <120 g/L in women 21.

Patients will be selected according to the usual practice, without excluding patients because of comorbidity or other reasons that may affect results (selection bias).

Prior to inclusion, freely given written informed consent will be obtained from all patients. Once included, each patient will be masked into a unique identity number (correlative according to inclusion), as a reference of patient ID in the registry.

Each patient will be randomised to a line A or line B of treatment.

  • Line A: a single, ferric carboxymaltose (Ferinject®) 1000 mg IV iron dose administration. The infusion will be according to product specifications with an approximate duration of 15 minutes during hospitalisation and will not require an additional site visit or extended period of hospitalisation.
  • Line B: control. The control group will not receive specific treatment. In case of severe iron deficiency anaemia, oral iron supplements (iron sulphate dihydrate) will be given.

Both lines may be followed in addition to taking vitamin B12 and folic acid, if indicated.

The patient, once included in the study, may receive a blood transfusion if the following criteria are met:

  • Absolute indication: Hemodynamic instability Active bleeding Hb <7 g/dl
  • Relative indications: in case of Hb <8.5 g/dL or haematocrit <28% following the clinical criteria of the medical specialist.

Interventions to be measured:

The data collected at baseline will include patients' past medical history, medications, blood tests (including hemogram, iron tests and renal function), comorbidity index (Charlson Scale), lower limbs chronic ischemia category and the limb scheduled for revascularisation (including registry of any trophic lesions and if they have signs of active infection), height, weight and body-mass index of the patient. In addition, already validated quality of life questionnaire, the Short Form-36 Health Survey (SF-36) will be completed.

Procedure data will record: date of IV iron treatment, if received, dose and any adverse events during or after administration; ASA (American Society of Anaesthesiologists) risk level; type of surgery performed for revascularisation of lower limbs, information on clinical success and complications of the intervention. Blood records will include haemoglobin before and first day after surgery and number of red blood cell units of or any other blood component transfused during the surgical procedure. If surgery does not finally take place, data from the 30 days after inclusion will be registered for analysis with intention to treat.

The hospital discharge visit will record: date of discharge; last hemogram; number of blood transfusions from the postoperative period until discharge; days in intensive care; adverse events such as medical and surgical complications as well as mortality.

The final follow-up visit will take place 30 days after the main surgery (with + 7 day window) it would be performed by telephone, in the outpatient consultation or in the hospital if the patient continues to be hospitalised; in that case, the discharge visit and final visit will be made simultaneously. It will record: blood tests (including hemogram, iron tests), clinical success, serious adverse events (SAE) and mortality, which may have occurred between hospital discharge and the visit in addition to Short Form-36 Health Survey (SF-36). See Fig. 1 for Assessment flow diagram.

Details
Condition Anemia, Peripheral Arterial Occlusive Disease
Treatment Ferric Carboxymaltose Injection [Injectafer], Ferric Carboxymaltose Injection [Injectafer], no treatment or oral iron supplementation
Clinical Study IdentifierNCT04083755
SponsorBiocruces Bizkaia Health Research Institute
Last Modified on20 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients of both sexes over 18 years
Patients diagnosed with anemia, considered as Hb <13.0 g/dL in mens and Hb<12g/dL in women
Patients diagnosed with symptomatic chronic lower limb ischemia (degrees 2-5 by Rutherford-Baker, both included, Fontaine II-IV), who will undergo surgical revascularization (endovascular or open) and accept treatment
Revascularization surgery scheduled in the approximate minimum period of two days, (> 48 hours) from the inclusion
They are able and willing to give written informed consent at the time of selection

Exclusion Criteria

Patients with acute ischemia will be excluded
Severe anemia < 8 gr/dL
Arterial hypertension not controlled with antihypertensive medication (considered with systolic blood pressure> 180mmHg or diastolic> 100mmHg)
Acute renal failure or renal failure with creatinine clearance <30mmHg
Patient with documented intolerance or allergy to iron or its derivatives
Unstable angina, defined as electrocardiographic changes with chest pain that indicate resting myocardial ischemia
History of stroke in the previous 6 months
Patients with thrombocytopenia less than 50,000ug/dl or alterations in coagulation
That you are simultaneously participating in a clinical trial that conditions or modifies the registry
Patients already diagnosed with iron-deficiency anemia in oral iron treatment in their usual medication
Pregnancy or lactation (pregnancy tests in women of childbearing age according to usual practice)
Rejection of treatment or inclusion in the registry by the patient
Patients who refuse to receive transfusions of blood products (for example, Jehovah's Witnesses)
Patients with criteria of SEPSIS
Patients with Ferritin <30 ng/ml that will be directed for digestive study
Patients with active neoplasia
Patients who are not able to give their informed consent or understand the study procedure
Probable or confirmed case with active SARS-CoV-2 infection
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note